Clinical Trial Update: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates Lexaptepid pegol (NOX-H94) for ESA-hyporesponsive anemia in dialysis patients has completed Phase 1/Phase 2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• End-stage Renal Disease

Drugs mentioned

• Lexaptepid pegol (NOX-H94)

Snippet

Sponsor: TME Pharma AG | Conditions: Anemia, End Stage Renal Disease | Phase 1, Phase 2 | Status: COMPLETED